ASX ANNOUNCEMENT

L-Dex® Recommended in Clinical Practice Guidelines

Brisbane, Australia, and Carlsbad, Calif. - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, is pleased to announce that the Oncology Section of the American Physical Therapy Association (APTA) has developed and published an evidence-based, clinical practice guideline for lymphoedema diagnosis and management.

The APTA is an organisation of professional Physical Therapists managing the needs of patients resulting from the treatment of active cancer disease. The oncology section commissioned the writing of evidence based guidelines for secondary lymphoedema in cancer survivors.

This clinical practice guideline recommends L-Dex for patients at risk of, or with early stage, lymphoedema of the arm for both detection and ongoing management.

The practice recommendations specifically state different appropriate cutoff values for L-Dex dependent on whether a patient has had a pre-operative assessment or not. In a podcast, the authors said “in some groups with early or subclinical lymphedema, volume measures may not be sensitive enough to diagnose and/or assess extracellular fluid.”

An executive summary of the Clinical Practice Guidelines will be published in Rehabilitation Oncology’s July issue.

“This scientific and independent review that lead to the recommendation of L-Dex for the early detection and management of secondary lymphoedema is significant. We see these guidelines as a major step forward in our journey to make L-Dex the standard of care for cancer survivors at risk of developing lymphoedema,” said Richard Carreon, Managing Director and CEO of ImpediMed.

Richard Carreon
Managing Director & CEO

For further information, contact:
Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Media Contact:
Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au
About ImpediMed
Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex® device. In addition, ImpediMed produces a family of CE Marked medical devices, including SOZO™, sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).